✦ LIBER ✦

1228 Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumours

✍ Scribed by G. Citterio; F.G. De Braud; V. Gregorc; T.M. De Pas; C. Noberasco; S. Boselli; M. Giovannini; F. Caligaris Cappio; A. Lambiase; C. Bordignon

Book ID: 119600201
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 51 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(09)70440-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6617 Phase II study of NGR-hTNF, a selec

6617 Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients (pts) with advanced hepatocellular carcinoma (HCC)

✍ Santoro, A.; Citterio, G.; Pressiani, T.; Gregorc, V.; Rimassa, L.; De Braud, F. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

6062 NGR-hTNF, a vascular targeting agen

6062 NGR-hTNF, a vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) failing standard regimens: a phase II study

✍ Rimassa, L.; Santoro, A.; Sobrero, A.F.; Sclafani, F.; Gregorc, V.; Andretta, V. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Phase Ib study of NGR–hTNF, a selective

Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

✍ Gregorc, V; Santoro, A; Bennicelli, E; Punt, C J A; Citterio, G; Timmer-Bonte, J 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 216 KB

9011 NGR-hTNF, a vascular targeting agen

9011 NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study

✍ Gregorc, V.; Ceresoli, G.L.; Zucali, P.A.; De Braud, F.G.; Bajetta, E.; Santoro, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

366 POSTER Phase I study of NGR-TNF, a n

366 POSTER Phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumours (EORTC 16041)

✍ C. Van Herpen; W. Fiedler; S. Toma; S. Marreaud; H. Van Laarhoven; P. Lasch; J. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB

1205 ORAL Phase I and Pharmacodynamic St

1205 ORAL Phase I and Pharmacodynamic Study of High-dose NGR-hTNF in Patients With Refractory Solid Tumours

✍ P.A. Zucali; A. Santoro; M. Simonelli; F. De Vincenzo; E. Lorenzi; L. Rimassa; L 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 62 KB